"Survival Rate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
| Descriptor ID |
D015996
|
| MeSH Number(s) |
E05.318.308.985.550.900 N01.224.935.698.826 N06.850.505.400.975.550.900 N06.850.520.308.985.550.900
|
| Concept/Terms |
Survival Rate- Survival Rate
- Rate, Survival
- Rates, Survival
- Survival Rates
Mean Survival Time- Mean Survival Time
- Mean Survival Times
- Survival Time, Mean
- Survival Times, Mean
- Time, Mean Survival
- Times, Mean Survival
Cumulative Survival Rate- Cumulative Survival Rate
- Cumulative Survival Rates
- Rate, Cumulative Survival
- Rates, Cumulative Survival
- Survival Rate, Cumulative
- Survival Rates, Cumulative
|
Below are MeSH descriptors whose meaning is more general than "Survival Rate".
Below are MeSH descriptors whose meaning is more specific than "Survival Rate".
This graph shows the total number of publications written about "Survival Rate" by people in this website by year, and whether "Survival Rate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 23 | 23 |
| 1997 | 0 | 32 | 32 |
| 1998 | 0 | 42 | 42 |
| 1999 | 0 | 26 | 26 |
| 2000 | 0 | 34 | 34 |
| 2001 | 0 | 29 | 29 |
| 2002 | 0 | 30 | 30 |
| 2003 | 1 | 31 | 32 |
| 2004 | 0 | 32 | 32 |
| 2005 | 0 | 32 | 32 |
| 2006 | 0 | 33 | 33 |
| 2007 | 0 | 24 | 24 |
| 2008 | 0 | 53 | 53 |
| 2009 | 0 | 39 | 39 |
| 2010 | 0 | 71 | 71 |
| 2011 | 0 | 73 | 73 |
| 2012 | 0 | 59 | 59 |
| 2013 | 1 | 59 | 60 |
| 2014 | 0 | 56 | 56 |
| 2015 | 0 | 56 | 56 |
| 2016 | 1 | 60 | 61 |
| 2017 | 0 | 64 | 64 |
| 2018 | 1 | 49 | 50 |
| 2019 | 0 | 87 | 87 |
| 2020 | 0 | 65 | 65 |
| 2021 | 0 | 40 | 40 |
| 2022 | 0 | 11 | 11 |
| 2023 | 0 | 8 | 8 |
| 2024 | 0 | 42 | 42 |
| 2025 | 0 | 27 | 27 |
To return to the timeline,
click here.
Below are the most recent publications written about "Survival Rate" by people in Profiles.
-
Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology). Leukemia. 2025 Dec; 39(12):2926-2934.
-
Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model. Leukemia. 2025 Nov; 39(11):2697-2707.
-
Outcomes for Patients Aged 12-18 Months With Metastatic MYCN Non-Amplified Neuroblastoma and Unfavorable Biologic Features ("Mixed Biology Toddlers"): A Report From the International Neuroblastoma Risk Group (INRG) Project. Pediatr Blood Cancer. 2025 Nov; 72(11):e31968.
-
Procedure Patterns and Survival in Advanced Non-Small Cell Lung Cancer With Malignant Airway Obstruction: A Surveillance, Epidemiology, and End Results Medicare Analysis. Chest. 2026 Feb; 169(2):538-549.
-
Outcomes with Impella CP in acute myocardial infarction vs heart failure cardiogenic shock: Insights from the Cardiogenic Shock Working Group. J Heart Lung Transplant. 2026 Feb; 45(2):262-272.
-
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study. Clin Lung Cancer. 2025 Dec; 26(8):626-641.
-
Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials. J Thorac Oncol. 2025 Dec; 20(12):1778-1790.
-
The role of extent of resection, chemoradiation, and MGMT promoter methylation in overall survival in a large cohort of IDH-wildtype glioblastoma. Neurosurg Focus. 2025 08 01; 59(2):E9.
-
Development of a risk score predicting survival after adult heart transplantation in the United States. J Heart Lung Transplant. 2025 Dec; 44(12):1874-1882.
-
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results. Clin Lung Cancer. 2025 Nov; 26(7):541-551.